title: Payers Have Biologic Alternative for Patients With Moderate to Severe Rheumatoid Arthritis Who Do Not Respond to Other DMARD Therapies.
abstract: Earlier biologic therapies for rheumatoid arthritis represented a breakthrough in treatment of the disease, but there are still some patients who do not respond adequately to them. The market entry of abatacept, which allows for consistent dosing and predictable drug-acquisition costs, presents patients, physicians, and third-party payers with an effective alternative - the first therapy proven to be effective in patients with inadequate response to DMARDs such as methotrexate or anti-TNF-alpha therapies.
authors: Sally
authors: S
authors: Bell
references: Arthritis Rheum. 1998 May;41(5):778-99
references: 9588729
references: N Engl J Med. 2005 Sep 15;353(11):1114-23
references: 16162882
references: Arthritis Rheum. 2002 Feb;46(2):328-46
references: 11840435
references: J Clin Pharmacol. 2005 Jul;45(7):751-62
references: 15951465
references: Eur J Immunol. 2000 Dec;30(12):3707-17
references: 11169414
references: Ann Intern Med. 2006 Jun 20;144(12):865-76
references: 16785475
references: Curr Opin Rheumatol. 2004 May;16(3):212-7
references: 15103247
references: J Immunol. 1999 Jun 1;162(11):6708-15
references: 10352289
references: Nat Rev Drug Discov. 2003 Jun;2(6):473-88
references: 12776222